First-line fulvestrant plus anastrozole for hormone-receptor-positive metastatic breast cancer in postmenopausal women: a cost-effectiveness analysis

Weiting Liao; Jiaxing Huang; Qiuji Wu; Feng Wen; Nan Zhang; Kexun Zhou; Liangliang Bai; Qiu Li

doi:10.1007/s12282-019-01034-6

First-line fulvestrant plus anastrozole for hormone-receptor-positive metastatic breast cancer in postmenopausal women: a cost-effectiveness analysis

Breast Cancer ◽

10.1007/s12282-019-01034-6 ◽

2019 ◽

Vol 27 (3) ◽

pp. 399-404 ◽

Cited By ~ 1

Author(s):

Weiting Liao ◽

Jiaxing Huang ◽

Qiuji Wu ◽

Feng Wen ◽

Nan Zhang ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Cost Effectiveness ◽

Postmenopausal Women ◽

Hormone Receptor ◽

Metastatic Breast ◽

Cost Effectiveness Analysis ◽

First Line ◽

Hormone Receptor Positive ◽

Effectiveness Analysis

Download Full-text

Erratum to: Cost-effectiveness analysis of everolimus plus exemestane versus exemestane alone for treatment of hormone receptor positive metastatic breast cancer

Breast Cancer Research and Treatment ◽

10.1007/s10549-014-3107-3 ◽

2014 ◽

Vol 147 (2) ◽

pp. 443-443 ◽

Cited By ~ 1

Author(s):

Vakaramoko Diaby ◽

Georges Adunlin ◽

Simon B. Zeichner ◽

Kiran Avancha ◽

Gilberto Lopes ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Cost Effectiveness ◽

Hormone Receptor ◽

Metastatic Breast ◽

Cost Effectiveness Analysis ◽

Hormone Receptor Positive ◽

Effectiveness Analysis

Download Full-text

Cost Effectiveness Analysis of Exemestane Versus Capecitabine Monotherapy for Patients with Hormone Receptor–Positive and Her2-Negative, Metastatic Breast Cancer from National Cancer Institute Prespective in Egypt

Value in Health ◽

10.1016/j.jval.2017.08.207 ◽

2017 ◽

Vol 20 (9) ◽

pp. A434

Author(s):

H Abdallah ◽

AS Abourawash ◽

M Elgazzar ◽

A Helal

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Cost Effectiveness ◽

National Cancer Institute ◽

Hormone Receptor ◽

Metastatic Breast ◽

Cost Effectiveness Analysis ◽

Hormone Receptor Positive ◽

Effectiveness Analysis

Download Full-text

Cost-effectiveness analysis of everolimus plus exemestane versus exemestane alone for treatment of hormone receptor positive metastatic breast cancer

Breast Cancer Research and Treatment ◽

10.1007/s10549-014-3042-3 ◽

2014 ◽

Vol 147 (2) ◽

pp. 433-441 ◽

Cited By ~ 11

Author(s):

Vakaramoko Diaby ◽

Georges Adunlin ◽

Simon B. Zeichner ◽

Kiran Avancha ◽

Gilberto Lopes ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Cost Effectiveness ◽

Hormone Receptor ◽

Metastatic Breast ◽

Cost Effectiveness Analysis ◽

Hormone Receptor Positive ◽

Effectiveness Analysis

Download Full-text

Cost-Effectiveness Analysis of Fulvestrant 500 mg in Endocrine Therapy-Naïve Postmenopausal Women with Hormone Receptor-Positive Advanced Breast Cancer in the UK

PharmacoEconomics - Open ◽

10.1007/s41669-019-0134-3 ◽

2019 ◽

Vol 3 (4) ◽

pp. 559-570 ◽

Cited By ~ 2

Author(s):

Claire Telford ◽

Evelina Bertranou ◽

Samuel Large ◽

Hilary Phelps ◽

Mattias Ekman ◽

...

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Endocrine Therapy ◽

Hormone Receptor ◽

Cost Effectiveness Analysis ◽

Hormone Receptor Positive ◽

Effectiveness Analysis ◽

The Uk

Download Full-text

PCN32 COST-EFFECTIVENESS ANALYSIS OF LETROZOLE VERSUS TAMOXIFEN AS INITIAL ADJUVANT THERAPY IN HORMONE-RECEPTOR POSITIVE POSTMENOPAUSAL WOMEN WITH EARLY BREAST CANCER IN THE UK

Value in Health ◽

10.1016/s1098-3015(10)67270-1 ◽

2005 ◽

Vol 8 (6) ◽

pp. A43

Author(s):

J Karnon ◽

TE Delea ◽

NL Papo ◽

V Barghout ◽

SK Thomas ◽

...

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Adjuvant Therapy ◽

Postmenopausal Women ◽

Early Breast Cancer ◽

Hormone Receptor ◽

Cost Effectiveness Analysis ◽

Hormone Receptor Positive ◽

Effectiveness Analysis ◽

The Uk

Download Full-text

Cost-effectiveness analysis of fulvestrant versus anastrozole as first-line treatment for hormone receptor-positive advanced breast cancer

European Journal of Cancer Care ◽

10.1111/ecc.12733 ◽

2017 ◽

Vol 26 (6) ◽

pp. e12733 ◽

Cited By ~ 10

Author(s):

H. Ding ◽

L. Fang ◽

W. Xin ◽

Y. Tong ◽

Q. Zhou ◽

...

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Advanced Breast Cancer ◽

Hormone Receptor ◽

Cost Effectiveness Analysis ◽

Line Treatment ◽

First Line ◽

Hormone Receptor Positive ◽

Effectiveness Analysis ◽

First Line Treatment

Download Full-text

Cost-effectiveness analysis of anastrozole ('Arimidex') versus tamoxifen as frist-line therapy in postmenopausal women with hormone receptor-positive (HR+) advanced breast cancer (ABC): A UK perspective

European Journal of Cancer ◽

10.1016/s0959-8049(02)80202-7 ◽

2002 ◽

Vol 38 (11) ◽

pp. S68

Author(s):

R Simons

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Hormone Receptor ◽

Cost Effectiveness Analysis ◽

Advanced Breast ◽

Hormone Receptor Positive ◽

Effectiveness Analysis ◽

Line Therapy

Download Full-text

Efficacy of Letrozole as First-Line Treatment of Postmenopausal Women with Hormone Receptor–Positive Metastatic Breast Cancer in Korea

Cancer Research and Treatment ◽

10.4143/crt.2016.259 ◽

2017 ◽

Vol 49 (2) ◽

pp. 454-463 ◽

Cited By ~ 1

Author(s):

Seung Hoon Beom ◽

Jisu Oh ◽

Tae-Yong Kim ◽

Kyung-Hun Lee ◽

Yaewon Yang ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Postmenopausal Women ◽

Hormone Receptor ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Hormone Receptor Positive ◽

First Line Treatment

Download Full-text

Cost-effectiveness analysis of ribociclib versus palbociclib in the first-line treatment of HR+/HER2– advanced or metastatic breast cancer in Spain

ClinicoEconomics and Outcomes Research ◽

10.2147/ceor.s178934 ◽

2018 ◽

Vol Volume 10 ◽

pp. 773-790 ◽

Cited By ~ 7

Author(s):

Elena Galve-Calvo ◽

Eva González-Haba ◽

Joana Gostkorzewicz ◽

Irene Martínez ◽

Alejandro Pérez-Mitru

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Cost Effectiveness ◽

Metastatic Breast ◽

Cost Effectiveness Analysis ◽

Line Treatment ◽

First Line ◽

Effectiveness Analysis ◽

First Line Treatment

Download Full-text

A First Cost-Effectiveness Analysis Based on Real Life Clinical Outcomes of Bevacizumab+ Paclitaxel Compared to Paclitaxel Among French Patients with HER2- Metastatic Breast Cancer in First Line of Treatment

Value in Health ◽

10.1016/j.jval.2016.09.2232 ◽

2016 ◽

Vol 19 (7) ◽

pp. A737

Author(s):

A Petitjean ◽

S Roze ◽

B Tehard

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Cost Effectiveness ◽

Clinical Outcomes ◽

Real Life ◽

Metastatic Breast ◽

Cost Effectiveness Analysis ◽

First Line ◽

Effectiveness Analysis

Download Full-text